Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01486446 · ClinicalTrials.gov registry record · Phase 1
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
A Phase 1 study, sponsored by Xenon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01486446 is a Phase 1 study that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT01486446, a Phase 1 study, has completed, sponsored by Xenon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM). The purpose of this study is to determine whether XPF-002 is safe and effective in the treatment of pain caused by IEM.
Interventions
- DRUG Placebo
- DRUG XPF-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01486446
The ClinicalTrials.gov registry entry for NCT01486446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01486446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01486446 about?
NCT01486446 is a clinical study titled "Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia". This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM). The purpose of this study is to determine whether XPF-002 is safe and effective in the tr...
What is the current status of trial NCT01486446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2011-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01486446?
The interventions under investigation include: Placebo (DRUG), XPF-002 (DRUG).
Who is sponsoring clinical trial NCT01486446?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.